All In Biotech

Drug Trial Radar · NCT06130345

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran Vaccines in the United States

Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15,196,685

Actual

Start

Apr 14, 2023

Primary completion

Feb 29, 2024

Study completion Aug 31, 2024

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
Collaborators
Aetion, Inc.
First posted
Nov 14, 2023

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.

Conditions

  • SARS-CoV-2

Interventions

  • SPIKEVAXBiological

    Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events of Special Interest (AESI)Time frame: Day 2 up to Day 60 after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aetion, Inc

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.